Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01051921 · ClinicalTrials.gov registry record · Phase 2
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
A Phase 2 study of Hepatitis C, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 15
- Study locations
NCT01051921 is a Phase 2 study of Hepatitis C that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 67 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT01051921, a Phase 2 study of Hepatitis C, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to determine if the combination treatment of CTS-1027, pegylated interferon and ribavirin can improve the response rates in HCV patients who did not previously respond to pegylated interferon and ribavirin therapy.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG CTS-1027
- DRUG Pegylated interferon
Study Locations (15)
California
- Scripps Clinic - La Jolla
- VA Medical Center, San Diego - San Diego
Colorado
- University of Colorado Health Science Center - Denver
- South Denver Gastroenterology - Englewood
Texas
- Advanced Liver Therapies - Baylor College of Medicine - Houston
- VA Medical Center, Houston - Houston
Georgia
- Digestive Healthcare of Georgia - Atlanta
Louisiana
- Tulane University Health Sciences Center - New Orleans
Michigan
- Henry Ford Medical Center-Columbus - Novi
Minnesota
- MN Clinical Research Center - Plymouth
Missouri
- St. Louis University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01051921
The ClinicalTrials.gov registry entry for NCT01051921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (96% lower). The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT01051921 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT01051921 about?
NCT01051921 is a clinical study titled "Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders". The purpose of this study is to determine if the combination treatment of CTS-1027, pegylated interferon and ribavirin can improve the response rates in HCV patients who did not previously respond to pegylated interferon and ribavirin therapy.
What is the current status of trial NCT01051921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2010-01. Estimated completion is 2011-12.
What conditions does trial NCT01051921 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01051921?
The interventions under investigation include: Ribavirin (DRUG), CTS-1027 (DRUG), Pegylated interferon (DRUG).
Who is sponsoring clinical trial NCT01051921?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01051921 being conducted?
This trial has 15 study locations across California, Colorado, Georgia, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.